Sponsored Links
| Abbott And Enanta Announce Advancement Of Hepatitis C Collaboration |
 |
 |
 |
| Pharmacy - Pharma Industry - Biotech Industry | |||
|
Abbott (NYSE: ABT) and Enanta Pharmaceuticals announced the advancement of their Hepatitis C (HCV) collaboration into Phase 2 clinical trials. The trial will evaluate three HCV antiviral agents, including the investigational protease inhibitor ABT-450, part of the Abbott-Enanta collaboration, and polymerase inhibitors ABT-333 and ABT-072 currently being developed exclusively by Abbott... Read more: Pharma Industry / Biotech Industry News From Medical News Today
|